Skip to main content
Cynthia Dunbar, MD, Hematology, Bethesda, MD

Cynthia Elizabeth Dunbar MD


Physician

Join to View Full Profile
  • 5132 Rockville PikeRm 4EBethesda, MD 20892

  • Phone+1 301-496-5093

  • Fax+1 301-594-1290

Dr. Dunbar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 1984 - 1987
  • Harvard Medical School
    Harvard Medical SchoolClass of 1984

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1989 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2003

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
    Cynthia E. Dunbar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome(MDS) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Modeling Human Paroxysmal Nocturnal Hemoglobinuria Via CRISPR/Cas9 HSPC Gene Editing in Non-Human Primate 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • With Chemo, Blinatumomab Boosts DFS in Pediatric B-ALL
    With Chemo, Blinatumomab Boosts DFS in Pediatric B-ALLDecember 8th, 2024
  • Bispecific Combo New Standard for Pediatric Acute Lymphoblastic Leukemia, Experts Say
    Bispecific Combo New Standard for Pediatric Acute Lymphoblastic Leukemia, Experts SayDecember 7th, 2024
  • ASH 2024: What Blood Cancer Advances Could Change Practice?
    ASH 2024: What Blood Cancer Advances Could Change Practice?December 2nd, 2024
  • Join now to see all

Grant Support

  • Retroviral Mediated Gene Transfer Into Primate Hematopoietic CellsNational Heart, Lung, And Blood Institute2010–2011
  • Gene Transfer And Ex Vivo Manipulation Of Hematopoietic CellsNational Heart, Lung, And Blood Institute1998–2008
  • Gene Transfer And Ex Vivo Manipulation Of HematopoieticNational Heart, Lung, And Blood Institute2001–2006
  • Gene Transfer To Hematopoietic Progenitor, Stem, And Stromal CellsNational Heart, Lung, And Blood Institute1995–1997
  • Gene Transfer To Human Hematopoietic Progenitor, Stem, And Stromal CellsNational Heart, Lung, And Blood Institute1994
  • Preclinical And Clinical Gene Transfer To Human Hematopoietic Stem CellsNational Heart, Lung, And Blood Institute1992–1993
  • Investigation of underlying mechanisms and novel therapies for human acquired and congenital disorders of hematopoiesisNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
  • Investigation of underlying mechanisms and novel therapies for human acquired and congenital disorders of hematopoiesisNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
  • Macaque models for preclinical development of iPSCsNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
  • Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapiesNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
  • Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapiesNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
  • Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapiesNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: